NRIX Earnings Nurix Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–28 of 28
| Q3 2026 | 2026-08-31 | 4.73 | 2026-10-13 | 10-Q |
| Q2 2026 | 2026-05-31 | -0.81 | 2026-07-09 | 10-Q |
| Q1 2026 | 2026-02-28 | -0.79 | 2026-04-08 | 10-Q |
| Q4 2025 (derived) | 2025-11-30 | -0.83 | 2026-01-28 | 10-K |
| FY 2025 | 2025-11-30 | -3.05 | 2026-01-28 | 10-K |
| Q3 2025 | 2025-08-31 | -1.03 | 2025-10-09 | 10-Q |
| Q2 2025 | 2025-05-31 | -0.52 | 2025-07-09 | 10-Q |
| Q1 2025 | 2025-02-28 | -0.67 | 2025-04-08 | 10-Q |
| Q4 2024 (derived) | 2024-11-30 | -0.74 | 2025-01-28 | 10-K |
| FY 2024 | 2024-11-30 | -2.88 | 2025-01-28 | 10-K |
| Q3 2024 | 2024-08-31 | -0.67 | 2024-10-11 | 10-Q |
| Q2 2024 | 2024-05-31 | -0.71 | 2024-07-11 | 10-Q |
| Q1 2024 | 2024-02-29 | -0.76 | 2024-04-10 | 10-Q |
| Q4 2023 (derived) | 2023-11-30 | -0.77 | 2024-02-15 | 10-K |
| FY 2023 | 2023-11-30 | -2.65 | 2024-02-15 | 10-K |
| Q3 2023 | 2023-08-31 | -0.68 | 2023-10-12 | 10-Q |
| Q2 2023 | 2023-05-31 | -0.45 | 2023-07-13 | 10-Q |
| Q1 2023 | 2023-02-28 | -0.75 | 2023-04-13 | 10-Q |
| Q4 2022 (derived) | 2022-11-30 | -0.85 | 2023-02-09 | 10-K |
| FY 2022 | 2022-11-30 | -3.71 | 2023-02-09 | 10-K |
| Q3 2022 | 2022-08-31 | -0.90 | 2022-10-06 | 10-Q |
| Q2 2022 | 2022-05-31 | -1.01 | 2022-07-07 | 10-Q |
| Q1 2022 | 2022-02-28 | -0.95 | — | — |
| FY 2021 | 2021-11-30 | -2.73 | — | — |
| Q3 2021 | 2021-08-31 | -0.65 | — | — |
| Q2 2021 | 2021-05-31 | -0.60 | 2021-07-13 | 10-Q |
| Q3 2021 | 2020-08-31 | -1.09 | 2021-10-14 | 10-Q |
| Q2 2020 | 2020-05-31 | 0.00 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.